Dynamics of magnetic particles in cylindrical Halbach array: implications for magnetic cell separation and drug targeting

2010 ◽  
Vol 48 (8) ◽  
pp. 745-753 ◽  
Author(s):  
Peter Babinec ◽  
Andrej Krafčík ◽  
Melánia Babincová ◽  
Joseph Rosenecker
Keyword(s):  
Cell Separation ◽  
Drug Targeting ◽  
Magnetic Particles ◽  
Halbach Array ◽  
Magnetic Cell Separation

Magnetic Cell Separation Using Antibody Binding with Protein A Expressed on Bacterial Magnetic Particles

2004 ◽  
Vol 76 (21) ◽  
pp. 6207-6213 ◽  
Author(s):  
Motoki Kuhara ◽  
Haruko Takeyama ◽  
Tsuyoshi Tanaka ◽  
Tadashi Matsunaga
Keyword(s):  
Cell Separation ◽  
Magnetic Particles ◽  
Protein A ◽  
Antibody Binding ◽  
Magnetic Cell Separation ◽  
Bacterial Magnetic Particles

One-step separation of CD20+cells from whole blood using bacterial magnetic particles displaying protein G

2008 ◽  
Vol 1094 ◽  
Author(s):  
Masayuki Takahashi ◽  
Tomoko Yoshino ◽  
Haruko Takeyama ◽  
Tadashi Matsunaga
Keyword(s):  
Whole Blood ◽  
Cell Separation ◽  
Magnetic Particles ◽  
Permanent Magnets ◽  
Bilayer Membrane ◽  
Protein G ◽  
Target Cells ◽  
One Step ◽  
Magnetic Cell Separation ◽  
Bacterial Magnetic Particles

AbstractMagnetic separation of target cells from mixtures, such as peripheral blood and bone marrow, has considerable practical potential in research and medical applications. Among the current cell separation techniques, magnetic cell separation using immunomagnetic particles has been routinely applied and has proven rapidness and simplicity.Magnetospirillum magneticumAMB-1 synthesizes intracellular nano-sized bacterial magnetic particles (BacMPs) that are individually enveloped by a stable lipid bilayer membrane. BacMPs, which exhibit strong ferrimagnetism, can be collected easily with commercially available permanent magnets. In this study, a novel magnetic nanoparticle displaying protein G (protein G-BacMPs) was fabricated, and one-step cell separation for direct cell separation from whole blood was performed using the protein G-BacMPs. B lymphocytes (CD20+cells), which cover less than 0.3×10−2% of whole blood cells, were separated with 93% purity using protein G-BacMPs binding with anti-CD20 monoclonal antibodies. The results of this study demonstrate the utility of protein G-BacMPs and the magnetic cell separation approach based on protein G-BacMPs in numerous applications.

Magnetic cell separation using nano-sized bacterial magnetic particles with reconstructed magnetosome membrane

2008 ◽  
Vol 101 (3) ◽  
pp. 470-477 ◽  
Author(s):  
Tomoko Yoshino ◽  
Hisashi Hirabe ◽  
Masayuki Takahashi ◽  
Motoki Kuhara ◽  
Haruko Takeyama ◽  
...  
Keyword(s):  
Cell Separation ◽  
Magnetic Particles ◽  
Magnetic Cell Separation ◽  
Bacterial Magnetic Particles

scholarly journals Isolating astrocytes and neurons sequentially from postnatal murine brains with a magnetic cell separation technique

2014 ◽  
Vol 1 (2) ◽  
pp. 11 ◽  
Author(s):  
Maria Feldmann ◽  
Praneeti Pathipati ◽  
R Ann Sheldon ◽  
Xiangning Jiang ◽  
Donna M Ferriero
Keyword(s):  
Cell Separation ◽  
Separation Technique ◽  
Magnetic Cell Separation

Clinical Scale Enrichment and Expansion of Highly Pure CD25+Foxp3+ Regulatory T Cells.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3718-3718
Author(s):  
Carina Conrads ◽  
Jürgen Schmitz ◽  
Mario Assenmacher ◽  
Claudia Niemand ◽  
Alexander Scheffold
Keyword(s):  
Clinical Application ◽  
Cell Separation ◽  
Foxp3 Expression ◽  
Clinical Scale ◽  
Organ Rejection ◽  
Immune Mediated ◽  
In Vitro Expansion ◽  
Magnetic Cell Separation ◽  
Effector Cytokines

Abstract Abstract 3718 CD25+Foxp3+ regulatory T cell (Treg) bear great potential to prevent or treat a variety of immune mediated diseases, including autoimmunity, organ rejection or GvHD. Currently Treg for clinical application can be separated by magnetic cell separation via the CliniMACS® Plus Instrument using CD25 enrichment plus/minus prior depletion of CD8 or CD19 positive cells. With this technology Treg can be enriched to a mean purity of about 50% and first clinical trials for prevention of GvHD show no adverse effects at all. Despite these promising results, concerns have been raised whether in the setting of organ transplantation or autoimmunity higher Treg purities and/or the in vitro expansion of Treg without loss of Foxp3+ expression are required. Therefore, we have optimized the parameters for CD25 enrichment via CliniMACS to achieve higher purity of the isolated Treg. The purity of Treg could be increased by about 20–30% resulting in an average purity of 70–80% of Foxp3+ Treg. We have also developed a protocol for the in vitro expansion of CliniMACS isolated Treg using CD3/CD28 coated MACSiBead™Particles. In the presence of Rapamycin CliniMACS isolated Treg could be expanded about 20 fold with a single round of stimulation. Importantly Foxp3+ expression was not affected by the expansion but remained constant at about 70–80%. Similarly the expression of effector cytokines by expanded Treg was greatly suppressed by Rapamycin. These data show that Treg for clinical application can efficiently be isolated with high purity via CliniMACS and subsequently be expanded in vitro without loss of Foxp3 expression. Disclosures: Conrads: Miltenyi Biotec: Employment. Schmitz:Miltenyi Biotec: Employment. Assenmacher:m: Employment. Niemand:Miltenyi Biotec: Employment. Scheffold:Miltenyi Biotec: Employment.

Sign in / Sign up

Export Citation Format

Share Document